The story of Viagra, and its developer copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in sales , its intellectual property lapse created a deluge of generic competition , significantly impacting its dominance. While specific pharmaceutical companies may seek to capitalize on related treatment